Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Free cash flow margin
Johnson & Johnson's free cash flow margin over the twelve months to 30 June 2026 was 23.2%, up 1.5 percentage points from fiscal 2025 (21.7%). Over the past ten years it has ranged from 21.7% (fiscal 2025) to 28.3% (fiscal 2019) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 17.3% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 21.7% | (1.42) |
| FY2024 | 23.1% | 1.25 |
| FY2023 | 21.9% | (0.31) |
| FY2022 | 22.2% | (3.84) |
| FY2021 | 26.0% | 1.18 |
| FY2020 | 24.8% | (3.43) |
| FY2019 | 28.3% | 1.61 |
| FY2018 | 26.6% | 0.99 |
| FY2017 | 25.7% | 2.27 |
| FY2016 | 23.4% | (4.55) |
Against its own ten years
Low 21.7%
High 28.3%
Ten-year median
24.8%
Current reading's percentile
9
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. compare | 42.5% |
| ABBV AbbVie Inc. compare | 28.3% |
| NVS Novartis AG compare | 26.8% |
| AMGN Amgen Inc. compare | 26.7% |
| MRK Merck & Co., Inc. compare | 24.1% |
| JNJ Johnson & Johnson | 23.2% |
| LLY Eli Lilly and Company compare | 22.8% |
| PFE Pfizer Inc. compare | 17.3% |
| AZN AstraZeneca PLC compare | 10.2% |
| Drug Manufacturers General industry median | 17.3% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on JNJ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement